Janssen Biotech, Inc.

Ratiopharm Gmbh

Susann Taudte

Jinquan Luo

Raymond W Sweet

David A Zopf

Sheng-Jiun Wu

William Strohl

Caryn Bowe

Juan C Almagro

Michael Naso

Robert Rauchenberger

John Wheeler

Galina Obmolova

Thomas J Malia

Mark Tornetta

Mark Rutz

Colleen Kane

Patrick Branigan

Daniela Della Ducata

Merle Elloso

Bingyuan Wu

Henrik Clausen

Walter S Willett

Juan Carlos Almagro

The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).

Humanized IL-25 antibodies

Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

IL-17A antibodies

Growing community of inventors

Radnor, PA, United States of America

Susann Taudte